Business
UK launch of Feraccru® by Norgine
UK launch of Feraccru® by Norgine.
About this update from Shield Therapeutics Plc
[{"type":"text","content":"\n \nRNS Number : 5186J Shield Therapeutics PLC 05 December 2018 \n\nShield Therapeutics plc\n(\"Shield\" or the \"Group\")\nShield Therapeutics notes UK launch of Feraccru® by Norgine\n \nLondon, UK, 5 December 2018: Shield Therapeutics plc (LSE:STX), a commercial stage, pharmaceutical company delivering innovative specialty pharmaceuticals to address patients' unmet medical needs, is pleased to note the announcement today by Norgine that they have launched Feraccru® in the UK. Feraccru® is a novel, effective and well tolerated treatment for Iron Deficiency in adults. In September 2018, Shield licensed Feraccru® to Norgine B.V. in most European territories.\n \nCarl Sterritt, Chief Executive Officer of Shield Therapeutics, added: \"I am delighted that Norgine's UK team is now starting to promote Feraccru® in the UK. Since announcing the licence agreement in September 2018, we have been working closely with Norgine to transfer knowledge and responsibilities from Shield to them and the UK launch demonstrates that this transition period is progressing well.\"\n \n \n- Ends -\nFor further information please contact:\n \nShield Therapeutics plc +44 (0)207 186 8500\nCarl Sterritt, Chief Executive Officer\nTim Watts, Interim Chief Financial Officer\n \nNominated Advisor and Joint Broker +44 (0)203 100 2222\nLiberum Capital Limited\nChristopher Britton/Steve Pearce\n \nJoint Broker &nb...